if they can be used in 30m surgeries which is just over 1 in 2 surgeries, then we are looking at 3.5b in sales. With a forecasted 20% EBITA margin we are looking towards a $10B company. I think that re-rate will kick it off, but another 4-5 years, then it might over perform to $35/share which would be insane.
Market feedback, page-14
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NXS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.010(4.44%) |
Mkt cap ! $68.54M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 21.5¢ | $46.14K | 206.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 130676 | 21.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 19533 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NXS (ASX) Chart |